lines, enables rapid testing of many drugs against a large number of cancer cell lines in pools 6 . Molecular features of the cell lines (for example, gene expression, mutation, or copy-number variation) can then be used to identify predictive biomarkers of drug sensitivity (Supplementary Table 2 ). Finally, morphologic changes in cells can be assessed using high-throughput microscopy and machine-learning approaches. Such imaging-based screening unexpectedly identified the cholesterol drug lovastatin as a potent inhibitor of leukemia stem cells.
To take advantage of these advances in experimental methods, we sought to assemble a comprehensive library of drugs that have reached the clinic. Surprisingly, we found that no such chemical library of approved and clinical trial drugs is available for purchase. In particular, drugs that have been tested in clinical trials but did not reach approval are not readily accessible. Even obtaining a complete list of such drugs and their annotations is challenging. A prior effort led by the US National Institutes of Health (NIH) focused on drugs approved by the US Food and Drug Administration (FDA), but the library has few compounds that have yet to achieve FDA approval 7 . Some chemical vendors offer a subset of approved drugs, but most of these commercial libraries overlap in their content and include only a small fraction of the approximately 10,000 drugs that have reached the clinic in the United States and Europe. Given that no complete collection exists, we launched a three-step effort to create the Repurposing Library by (i) identifying and purchasing compounds; (ii) comprehensively annotating their known activities and clinical indications; and (iii) experimentally confirming drug identity and purity.
We employed two approaches to identify clinical-drug structures for the Repurposing Library. First, we searched existing databases, both publicly accessible and proprietary, for clinically tested drugs and then manually integrated them to ensure sufficient drug coverage and chemical-structure reliability (Supplementary Table 3) . Sources included DrugBank, the NCATS NCGC Pharmaceutical Collection (NPC), Thomson Reuters Integrity, Thomson Reuters Cortellis, and Citeline Pharmaprojects [7] [8] [9] . Second, we located marketed or approved ingredient lists from regulatory agencies worldwide, including the FDA. After structure standardization and the removal of duplicates, approximately 10,000 small-molecule drugs with disclosed structures were found to have reached clinical development. Most of these drugs are not widely available in commercial screening libraries. Through structure-matching (as opposed to relying on compound names), chemical suppliers were identified for 5,691 compounds (Fig. 1) The standardization of drug-mechanism and protein-target information enables experimental interpretation of repurposing efforts. Using a combination of publicly available databases and extensive manual curation, we found a total of 2,006 human proteins to be targeted by compounds in the Repurposing Library. Protein-target classification using a published database revealed that the most common drug-target categories are G-protein-coupled receptors, acetylcholine receptors, nonreceptor serine/threonine protein kinases, oxygenases, voltage-gated sodium channels, and nuclear hormone receptors (Fig. 2b,d ) 10 . Overall, 92% of compounds were successfully mapped to a human protein target or assigned a mechanism-of-action label (useful for anti-infectives and compounds without known human targets).
Surprisingly, we found that it was difficult to determine even the approved clinical indications for existing drugs. The availability of such information in public databases is highly variable, and in many cases, terminology is inconsistent. Using the NIH's DailyMed repository of FDA-approved drug-prescribing labels and other resources, we manually curated a dictionary of 644 unique drug-indication terms and assigned them to 1,918 launched drugs (Supplementary Fig. 2 ). The most common disease areas covered are neurology/psychiatry, infectious disease, cardiology, and endocrinology (Fig. 2c) . Although future repurposing opportunities will probably transcend these disease areas, knowledge of the existing drug indications is likely to prove useful.
Knowledge of drug patent and exclusivity status is necessary to identify commercial opportunities and funding mechanisms to conduct clinical trials for new indications. In the United States, the FDA Orange Book serves as an official reference for approved ingredients, therapeutic equivalency, and drug patents, as well as being the repository of exclusivity periods granted by the FDA. To harness these valuable annotations, we manually curated a mapping of compounds to the Orange Book, matching 1,412 of the obtained compounds (1,224 QC-confirmed) to the overall list of 1,576 unique ingredients reported by the FDA (excluding macromolecules, mixtures, radioactive substances, and redundant formulations). Among approved Repurposing Library drugs currently protected by substance patents, we observed an expected correlation between first-approval date, exclusivity end date, and patent expiration date (Supplementary Fig. 3) . Interestingly, there are more than 50 drugs with patents and/or exclusivity expiring more than 20 years after their original launch, which largely reflects the development of new indications and formulations that could be available for further repurposing. In cases where multiple drugs exist against the same target, such patent information can also aid in the selection of individual drugs for repurposing.
The final step in creating a drug-screening library is experimental confirmation of compound identity and purity. We therefore tested all compound samples in the Repurposing Library by ultra-performance liquid chromatography-mass spectrometry (UPLC-MS), after receipt of the compound structural diversity in the library. Compounds were clustered into 256 groups using a self-organizing map algorithm. As expected, compounds with known shared features generally clustered together (Supplementary Fig. 1a) . All but six clusters had at least one compound that was represented in the Repurposing Library, which reflects the high level of diversity of the Library overall. Poorly represented clusters consisted mostly of large macromolecules and polypeptide-derived drugs with a median molecular weight of 3,200 g per mol ( Supplementary  Fig. 1b) . We conclude from this analysis that the Repurposing Library is sufficiently representative of the majority of chemotypes that have reached clinical development.
With compounds in hand, the next challenge was to comprehensively annotate known drug functions and clinical-development status (Fig. 2) . This information was often inconsistent or contradictory across databases; manual curation from primary sources was therefore required. The FDA Orange Book, prescribing labels, ClinicalTrials.gov, PubMed, and other Internet resources were manually searched for clinical-status information. On the basis of this analysis, the quality control (QC)-confirmed Repurposing Library contains 1,988 launched drugs and 1,348 drugs that reached phases 1-3 of clinical development (Fig. 2a) . The library also includes 86 compounds that were previously approved but later withdrawn from use, and 1,285 preclinical or tool compounds 
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from the vendor. Surprisingly, 2,482 of 8,584 samples (29%) failed QC, defined as a purity of less than 85%, as measured by UPLC absorbance peak area at 210 nm, or by an evaporative light-scattering detector (ELSD) for peaks containing the expected compound mass (Supplementary Fig. 4a ).
The majority of QC failures were subsequently confirmed by the vendors of the compounds upon checking of the source stocks. Repeat sourcing of 527 failed compounds (purity of less than 85%) from one original vendor resulted in the rescue of 55% of those compounds (Supplementary Fig. 4b ).
The 984 unique compounds that still did not pass QC were excluded from the Repurposing Library. The majority of QC failures seem to have resulted from vendors storing compounds in DMSO, which has been well documented to result in low stability over time 11 .
To facilitate use of the resource by the scientific community, we have created an interactive Drug Repurposing Hub website, available at http://www.broadinstitute.org/repurposing (Supplementary Fig. 5 ). Users can search and view Repurposing Library compounds by clinical status, drug indication, disease areas, mechanism of action, drug target, purity, and/or vendor. Database exports are available as text files, and the underlying data can be accessed programmatically through a documented application-programming interface (API). We are unaware of such data being systematically available elsewhere. Screening-assay results at the Broad Institute will be made available through the website, and we encourage others who replicate the library to share their findings. Experimental results will be collected according to the principles developed for the NIH-funded BioAssay Research Database (BARD), which includes descriptions of experimental protocols using controlled vocabulary terms, as well as the ability to display compound-activity results from multiple-assay protocols.
The Drug Repurposing Hub is designed to rapidly identify drugs for evaluation in disease models. So far, there have been few resources available to connect the findings of disease-genetics studies to drugs available for preclinical and clinical testing. To illustrate the utility of the Drug Repurposing Hub in the identification of drugs targeting proteins encoded by recurrently mutated cancer-gene products, we queried the hub database with the 224 unique genes found to be statistically significantly mutated in a recent analysis of The Cancer Genome Atlas (TCGA) 12 . We found that 47% of significantly mutated cancer-gene products have a corresponding drug in the Repurposing Library that binds to the protein itself or a protein in a related pathway, or that recapitulates an established synthetic lethal interaction (Supplementary Fig. 6 ). Such mapping of gene-drug interactions will help to prioritize repurposing hypotheses for further testing.
Drug repurposing has enormous potential for rapid clinical impact, but there has not yet been a systematic effort to identify such opportunities. O x y g e n a s e D e h y d r o g e n a s e R e d u c t a s e N a + c h a n n e l V o lt a g e -g a te d N a + c h a n n e l K + c h a n n e l V o lt a g e -g a te d
K + c h a n n e l We have taken a foundational step forward by creating a robust information resource and comprehensive drug-screening library. As outlined by our results using the Drug Repurposing Hub, standardized and computable drug annotations will enable both global analysis and rapid individual drug lookups against specific targets, existing indications, or clinical-development status.
The integration of disparate resources, coupled with substantial manual curation, was necessary to identify clinical drugs, locate chemical suppliers, and standardize drug annotations. Through this process, we made two important observations that will affect the community's use of the Repurposing Hub. First, drug targets listed in public resources are often inconsistent and unreliable. To assist users in navigating discrepancies among literature-reported targets, we provide the provenance of the information for each target annotation, enabling users to investigate the evidence in the primary literature underlying each claim and to judge the level of consensus among different data sources. Second, our finding that 29% of purchased compound samples failed QC should serve as a reminder that experimental verification of compound identity and purity is essential, even when sourcing from established vendors.
We think that the Repurposing Library and Drug Repurposing Hub will serve as valuable resources for the scientific community and accelerate the search for new indications for existing drugs. We provide detailed sourcing information that makes it possible for others to readily generate the same physical library, thereby facilitating the comparison of results across multiple screening assays performed at different institutions. Although the Repurposing Library is the largest of its kind, it is not yet complete. Future work will focus on the identification of sources of missing compounds and on developing systematic assays that are suitable for new-indication discovery.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. 
